BioLargo, Inc.

Overview

BioLargo, Inc. is a cleantech company that invents, develops, and commercializes technologies for air quality, water treatment, energy storage, and medical applications. The company advances solutions through subsidiaries, partnerships, licensing, joint ventures, or sale of intellectual property.

Corporate structure

The company operates multiple wholly owned or partially owned subsidiaries focused on different technologies and markets:

• ONM Environmental, Inc. — Odor and VOC control products, flagship CupriDyne Clean, for consumer and industrial applications.
• BioLargo Equipment Solutions & Technologies, Inc. (BEST) — Water treatment equipment and solutions, including PFAS remediation (AEC) and water reuse (AROS).
• BioLargo Energy Technologies, Inc. (BETI) — Development of long-duration battery energy storage (Cellinity).
• Clyra Medical Technologies, Inc. — Medical device and wound care products based on copper-iodine technology (ViaCLYR, CICS).
• BLEST (BioLargo Engineering, Science & Technologies, LLC) — Professional engineering services division.
• BioLargo Canada, Inc. — R&D team based at the University of Alberta.
• BioLargo Development Corp. — Employee benefits and corporate services.

Business segments and core technologies

Odor and VOC control (consumer and industrial)

• ONM Environmental sells CupriDyne Clean and private-label odor-control products to municipalities, industrial sites (landfills, wastewater facilities), and consumer channels.
• The company has private-label licenses and related royalty arrangements; Pooph litigation arose from a license/royalty dispute and nonpayment.
• Services include engineering design, installation, maintenance, and on-site support for odor-control systems.

Water treatment equipment and solutions

• BEST develops and markets:
  • Aqueous Electrostatic Concentrator (AEC) for PFAS remediation — modular and scalable, produces less PFAS-laden waste than traditional methods.
  • AROS (Aqueous Reuse Optimization System) for minimal liquid discharge and industrial water reuse; co-developed with Garratt-Callahan and distributed via their sales force.
  • AOS (Advanced Oxidation System) for micropollutant removal (iodine-based oxidation); domestic development paused with potential European opportunities under consideration.
• BLEST provides engineering support for internal and external water projects and manages long, technically demanding sales cycles typical of the water sector.

Battery energy storage (Cellinity)

• BETI is developing a long-duration battery with a liquid sodium chemistry (Cellinity) aimed at safety, domestic sourcing, high cycle life, and low self-discharge.
• A pilot production facility is located in Oak Ridge, TN. Development efforts include larger cells and scalable manufacturing processes. The company has contemplated joint ventures for manufacturing, with BioLargo owning a minority stake and receiving royalties on JV revenues.

Medical technologies

• Clyra Medical focuses on wound care and infection management using a Copper-Iodine Complex Solution (CICS) and the ViaCLYR product line (a pH-balanced wound management solution).
• ViaCLYR received FDA 510(k) clearance. Keystone Industries is a manufacturing collaborator, and the first purchase order was received in February 2026.

Engineering services

• BLEST offers fee-for-service engineering to external clients and internal projects, including PFAS treatment and battery development support.

International / research

• BioLargo Canada conducts R&D at the University of Alberta campus in Edmonton.

Intellectual property

• Patent portfolio: 34 issued patents, including 26 in the United States, with an average remaining duration of seven years.
• The company protects its technologies with patents, trade secrets, and know-how and continues efforts to expand patent coverage as resources permit.

Key financial and operational details (as of year ended December 31, 2025)

• Net loss: $15,189,000 for 2025; includes a $3,886,000 credit loss expense related to a customer default that is subject to litigation. Net loss in 2024 was $4,347,000.
• Cash and liquidity: $3,883,000 in cash and cash equivalents as of December 31, 2025.
• Working capital and assets: Working capital of $51,000; current assets of $5,114,000 as of December 31, 2025.
• Cash from operations: Net cash used in operating activities was $8,297,000 in 2025.
• Research and development: R&D expense of $2,593,000 in 2025 (compared with $2,882,000 in 2024).
• Financing and equity activity (selected 2025 events):
  • Lincoln Park capital purchase agreement expired February 1, 2026; during 2025 BioLargo sold 11,745,123 shares to Lincoln Park for $2,122,000.
  • Private placements: $215,000 of common stock and warrants sold to accredited investors in 2025.
  • Clyra Medical and BETI-related equity activity: $2,339,000 of Clyra Medical common stock and $2,145,000 of Clyra Medical Series B Preferred Stock sold; $425,000 from BETI common stock.
  • 2024 comparable figures include sale of 766,175 Lincoln Park shares for $260,000.
• Intellectual property financing and risk: The company emphasizes patent protection but limits on resources affect filings and international protection; patent challenges remain a potential risk.
• Employees: 46 employees as of March 2, 2026; 44 full-time.

Real property and facilities

• BioLargo does not own real estate; leased facilities approximate:
  • 9,000 sq ft in Westminster, CA — principal offices and CupriDyne manufacturing for ONM.
  • 22,000 sq ft in Oak Ridge, TN — engineering division and BETI activities.
  • 450 sq ft (office) and 2,800 sq ft (warehouse/flex) in Tampa, FL — Clyra Medical.
  • ~1,500 sq ft in Edmonton, Canada — BioLargo Canada.

Facilities and offices

• Westminster, California — corporate headquarters and ONM facility (9,000 sq ft).
• Oak Ridge, Tennessee — BLEST operations and BETI activities (22,000 sq ft).
• Tampa, Florida — Clyra Medical offices and warehousing.
• Edmonton, Canada — BioLargo Canada R&D on the University of Alberta campus.

Customers and revenue notes

• Revenue declined 56% in 2025 after the company’s largest private-label customer ceased purchases.
• Pooph Inc. is referenced as a private-label customer involved in nonpayment and related litigation.

Key takeaways

• BioLargo operates a diversified cleantech portfolio across odor/VOC control, water treatment equipment, long-duration energy storage, and medical wound care, supported by engineering services and Canada-based R&D.
• The company funds operations primarily through equity financings and private placements.
• As of year-end 2025, BioLargo reported a net loss, modest cash balances, and ongoing liquidity needs that require additional financing.
• R&D and engineering services remain central to technology development and commercialization plans, supported by an active patent portfolio and pursued partnerships or licensing opportunities.